BioPharma Dive December 4, 2024
The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted interest from the likes of Bayer and Novo Nordisk.
Dewpoint Therapeutics, a young biotechnology company, could receive nearly half a billion dollars if all goes to plan in a new partnership focused on its experimental medicine for ALS.
Through a deal announced Wednesday, Dewpoint has given Mitsubishi Tanabe Pharma the exclusive right to license the medicine once it hits certain near-term research and development goals. Should Mitsubishi Tanabe choose to license the program, the Japan-based company would then be responsible for its clinical development and commercialization.
In exchange, Dewpoint has received an undisclosed upfront sum of money and could take home more through milestone...
Today's Sponsors
Today's Sponsor